Foscarbidopa-Foslevodopa (Vyalev)

Parkinson’s disease is a progressive neurodegenerative condition caused by a loss of dopaminergic neurons in the substantia nigra and dopamine depletion, which unbalances oscillatory neural transmission through the basal ganglia, resulting in bradykinesia. Risk factors for Parkinson’s disease include older age, genetics (e.g., family history), and environmental factors (e.g., exposure to certain pesticides and solvents). On October 17, 2024, the FDA approved foscarbidopa-foslevodopa (Vyalev) subcutaneous infusion for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. Foscarbidopafoslevodopa (Vyalev) is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Foscarbidopa and foslevodopa are converted in vivo to carbidopa and levodopa, respectively. <a id="